Merck Medicine - Search News

Merck licenses Chinese cancer drug

Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.

Reuters on MSN · 18h

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck to take over development of LaNova's LM-299,

Bloomberg L.P. · 18h

Merck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 Billion

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.

STAT · 15h

Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company

Seeking Alpha on MSN · 17h

Merck to buy rights to Chinese cancer drug for up to $3.3B

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected to obtain licensing rights to a cancer candidate known as LM-299 from the Chinese biotech in a deal worth up to $3.

Masimo to Present in Jefferies London Healthcare Conference

Business Wire · 8d

Merck to Participate in the UBS Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of general medicine,

Business Insider · 17h

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representatives. About Solid Biosciences Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne),

TMCnet · 16h

Masimo to Present in the Jefferies London Healthcare Conference

Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at A replay of the webcast will be available following the live presentation.

Yicai Global14m

Merck, Five Other Foreign Pharma Firms Get Nod to Offer Stem Cell, Gene Therapies in Shanghai FTZ

(Yicai) Nov. 15 -- The Germany’ Merck and five other overseas pharmaceutical companies have been given the green light to ...

14h

Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Yale Daily News1d

Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal

Merck was founded in 1668 and is the world’s oldest operating chemical and pharmaceutical company. Asuka Koda covers the ...

11h

Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

Daily23h

Ginkgo Bioworks advances collaboration with Merck to improve Biologics manufacturing

Boston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with ...

21h

Merck Foundation Marking "World Diabetes Day" by Providing out of 2080 Scholarships, 830 Scholarships for Diabetes and Hypertension in 52 Countries

BusinessWire India Accra [Ghana] Mumbai Maharashtra [India] November 14 Merck Foundation the philanthropic arm of Merck KGaA ...

Merck KGaA: Phase III Trial Of Pimicotinib In Tenosynovial Giant Cell Tumor Meets Primary Endpoint

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

Daily12d

Merck, Moderna begin Phase 3 Trial of V940 with Keytruda in non small lung cancer

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results